Avelas Biosciences to Present at JMP Securities Annual Life Sciences Conference
SAN DIEGO, June 14, 2018 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused platform technology company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced that Carmine N. Stengone, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 1:30 p.m. EDT (10:30 a.m. PDT) in New York City.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.
VIAVI Solutions ("VIAVI") notes the announcement made by Keysight Technologies, Inc. ("Keysight") and Spirent Communications plc ("Spirent") on March 28, 2024, of a recommended cash acquisition of Spirent by Keysight.
VIAVI believes that its...
Policybazaar, India's leading online insurance marketplace, is witnessing a significant increase in non-resident Indians (NRIs) choosing term insurance from India via its platform. This surge is driven by the unparalleled ease, affordability and...
TRON Forum (Chair: Ken Sakamura, Professor Emeritus of the University of Tokyo) is pleased to announce that four microcontroller manufacturers, Infineon Technologies Japan K.K. (President & CEO: Ikuya Kawasaki), STMicroelectronics K.K. (Country...
Frost & Sullivan recently researched the data center colocation services industry and, based on its findings, recognizes STT GDC India with the 2023 Indian Company of the Year Award. STT GDC India is a pioneer data center solutions provider that...
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...